Yahoo
NYSE American - Delayed Quote USD

OS Therapies Incorporated (OSTX)

1.2500 +0.0200 (+1.63%)
At close: October 28 at 4:00:00 PM EDT
1.2400 -0.0100 (-0.80%)
After hours: October 28 at 5:55:06 PM EDT
Chart Range Bar
Loading chart for OSTX
Chart does not reflect overnight price.
  • Previous Close 1.2300
  • Open 1.2400
  • Bid 1.2200 x 270000
  • Ask 1.3000 x 710000
  • Day's Range 1.2200 - 1.2800
  • 52 Week Range 1.1500 - 2.2500
  • Volume 273,836
  • Avg. Volume 585,298
  • Market Cap (intraday) 58.507M
  • Beta (5Y Monthly) -0.64
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1000
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 8.50
  • Zacks Rating Bullish

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.

ostherapies.com

4

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OSTX
10.71%
S&P 500 (^GSPC)
13.13%

1-Year Return

OSTX
33.16%
S&P 500 (^GSPC)
12.38%

3-Year Return

OSTX
68.75%
S&P 500 (^GSPC)
88.08%

5-Year Return

OSTX
68.75%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -8.63M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00
8.50 Average
1.2500 Current
13.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/9/2026
Analyst Roth Capital
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 7

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    56.63M

  • Enterprise Value

    57.50M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -232.65%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -39.37M

  • Diluted EPS (ttm)

    -1.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    205.03k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.69M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.2500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: